ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos.
Autor(a) principal: | |
---|---|
Data de Publicação: | 2006 |
Tipo de documento: | Tese |
Idioma: | por |
Título da fonte: | Biblioteca Digital de Teses e Dissertações da UFC |
Texto Completo: | http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=57 |
Resumo: | We investigate in this work the role of the central nervous system in the modulation of the inflammatory peripheral pain in the zymosan induced arthritis (AZy) in rats. Cerebrospinal fluid (CSF) and sinovial fluid were collected from animals at different AZy times (1, 3, 6, 12 and 14 hours) in order to determine the nitrite level. Different groups of male, Wistar rats (n=6), 250 to 300g weight, were then submitted to surgery in order to place a cannula in the subarachnoid space, to allow for intrathecal (i.t) insertion of substances. The animals were also submitted to AZy followed by the paw suspension test (PST) that measures articular incapacitation (AI), aiming to analyze hyperalgesia in this experimental model. The pharmacological modulation was achieved by the prophylactic or therapeutic i.t administration of a NO donor (SIN-1), NOS inhibitors (L-NAME, 1400W), a soluble Guanylate cyclase inhibitor (ODQ), a GMPc analogue (8-Bromo-GMPc) and an NMDA receptor antagonist (MK-801). The ODQ was also administered intraarticulary to one group of animals. The results are expressed as mean  s.e.m, followed by ANOVA and the Tukey test, comparing to the groups that received the vehicle. The levels of nitrite in the CSF were smaller at 1 and 3 hours after zymosan injection, as compared with basal levels (P<0.05). The surgical procedure did not alter hyperalgesia. SIN-1 i.t (10 mcg) reduced the AI, while 40mcg increased the AI (P<0.05). L-NAME or 1400W, prophylactic or therapeutic, reduced the AI (P<0.05). ODQ i.t, prophylactic, but not therapeutic, reduced the AI, and also reverted the AI promoted by the 40mcg of SIN-1. Besides, ODQ, intraarticulary, reverted the AI promoted by the 40mcg of SIN-1, administered i.t. MK-801 i.t inhibited the AI, both caused by AZy and by the 40mcg of SIN-1. The results suggest a central endogenous anti-nociceptive role of NO in the acute articular hyperalgesia of the AZy. The NO, depending on the dose and local where it acts, may present an anti-nociceptive or pro-nociceptive effect in the AZy, both due to the activation of GMPc and the excitation of NMDA receptors. We have shown, for the first time, the existence of a peripheral-central activation way modulating the articular hyperalgesia in the AZy acute phase. |
id |
UFC_55f14ff919674efe92d1bbe1445ca9e0 |
---|---|
oai_identifier_str |
oai:www.teses.ufc.br:169 |
network_acronym_str |
UFC |
network_name_str |
Biblioteca Digital de Teses e Dissertações da UFC |
spelling |
info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos. Nitric oxide (NO) participation in central hyperralgesia modulation in modulation in the zymozan induced artritis (AZy) in rats.2006-03-15Francisco Airton Castro da Rocha23373474353http://lattes.cnpq.br/4916026652021507Geanne Matos de Andrade21911258320http://lattes.cnpq.br/9935129797137635Carlos MaurÃcio de Castro Costa01356810306http://lattes.cnpq.br/9291210203141568 Diana CÃlia Sousa Nunes-Pinheiro15563278387http://lattes.cnpq.br/3376562859305916Maria Josà Pereira Vilar15479110420http://lattes.cnpq.br/426536992247093746447512353http://lattes.cnpq.br/5491102217675347VirgÃnia ClÃudia Carneiro GirÃoUniversidade Federal do CearÃPrograma de PÃs-GraduaÃÃo em FarmacologiaUFCBRArtrite Dor Ãxido NÃtricoArtritis Pain Nitric OxideFARMACOLOGIAWe investigate in this work the role of the central nervous system in the modulation of the inflammatory peripheral pain in the zymosan induced arthritis (AZy) in rats. Cerebrospinal fluid (CSF) and sinovial fluid were collected from animals at different AZy times (1, 3, 6, 12 and 14 hours) in order to determine the nitrite level. Different groups of male, Wistar rats (n=6), 250 to 300g weight, were then submitted to surgery in order to place a cannula in the subarachnoid space, to allow for intrathecal (i.t) insertion of substances. The animals were also submitted to AZy followed by the paw suspension test (PST) that measures articular incapacitation (AI), aiming to analyze hyperalgesia in this experimental model. The pharmacological modulation was achieved by the prophylactic or therapeutic i.t administration of a NO donor (SIN-1), NOS inhibitors (L-NAME, 1400W), a soluble Guanylate cyclase inhibitor (ODQ), a GMPc analogue (8-Bromo-GMPc) and an NMDA receptor antagonist (MK-801). The ODQ was also administered intraarticulary to one group of animals. The results are expressed as mean  s.e.m, followed by ANOVA and the Tukey test, comparing to the groups that received the vehicle. The levels of nitrite in the CSF were smaller at 1 and 3 hours after zymosan injection, as compared with basal levels (P<0.05). The surgical procedure did not alter hyperalgesia. SIN-1 i.t (10 mcg) reduced the AI, while 40mcg increased the AI (P<0.05). L-NAME or 1400W, prophylactic or therapeutic, reduced the AI (P<0.05). ODQ i.t, prophylactic, but not therapeutic, reduced the AI, and also reverted the AI promoted by the 40mcg of SIN-1. Besides, ODQ, intraarticulary, reverted the AI promoted by the 40mcg of SIN-1, administered i.t. MK-801 i.t inhibited the AI, both caused by AZy and by the 40mcg of SIN-1. The results suggest a central endogenous anti-nociceptive role of NO in the acute articular hyperalgesia of the AZy. The NO, depending on the dose and local where it acts, may present an anti-nociceptive or pro-nociceptive effect in the AZy, both due to the activation of GMPc and the excitation of NMDA receptors. We have shown, for the first time, the existence of a peripheral-central activation way modulating the articular hyperalgesia in the AZy acute phase.Nesse trabalho, investigamos a participaÃÃo do sistema nervoso central (SNC) na modulaÃÃo da dor inflamatÃria perifÃrica na artrite induzida por zymosan (AZy) em ratos. Coletou-se o lÃquor (LCR) e lavado articular dos animais em diferentes tempos de artrite (1, 3, 6, 12 e 24 horas) para a determinaÃÃo dos nÃveis de nitrito. Em seguida, diferentes grupos de ratos (n=6) machos, Wistar, pesando entre 250 300g, foram submetidos ao procedimento cirÃrgico para colocaÃÃo de uma cÃnula no espaÃo subaracnÃideo, para permitir a administraÃÃo intratecal (i.t) de substÃncias. Os animais foram tambÃm submetidos à artrite induzida por zymosan (AZy) seguida da realizaÃÃo do teste de suspensÃo da pata (TSP) para permitir a avaliaÃÃo da incapacitaÃÃo articular (IA), refletindo a hiperalgesia no modelo. A modulaÃÃo farmacolÃgica foi realizada atravÃs da administraÃÃo i.t, de forma profilÃtica ou terapÃutica, de um doador de NO (SIN-1), de inibidores de NOS (L-NAME, 1400W), de um inibidor da guanilato ciclase solÃvel (ODQ), de um anÃlogo do GMPc (8-Bromo-GMPc) e de um antagonista dos receptores NMDA (MK-801). Em um grupo, o ODQ foi tambÃm administrado por via i.a. Os resultados foram expressos em mÃdia  e.p.m., seguida de ANOVA e Teste de Tukey, comparando-se aos grupos que receberam o veÃculo. Os nÃveis de nitrito no LCR foram menores à 1 e 3 h apÃs a injeÃÃo do zymosan, em relaÃÃo aos valores basais (P<0,05). O procedimento cirÃrgico nÃo alterou a hiperalgesia. SIN-1 i.t (10mcg) reduziu a IA, mas 40 mcg de SIN-1 aumentaram a IA (P<0,05). L-NAME ou 1400W, de forma profilÃtica ou terapÃutica, reduziram a IA (P<0,05). ODQ i.t, profilÃtico, mas nÃo terapÃutico, reduziu a IA da AZy e tambÃm reverteu a IA promovida por 40mcg de SIN-1. Ainda, ODQ, intra-articular, reverteu a IA promovida por 40mcg de SIN-1, i.t., MK-801 i.t inibiu a IA tanto da AZy quanto de 40mcg de SIN-1. Os resultados sugerem um papel antinociceptivo endÃgeno central do NO na hiperalgesia articular aguda da AZy. O NO, a depender da dose e do local de aÃÃo, pode ter efeito prà ou anti-nociceptivo, por ativaÃÃo de GMPc e excitaÃÃo de receptores NMDA. De forma inÃdita, demonstramos a existÃncia de uma via de ativaÃÃo perifÃrico-central modulando a hiperalgesia articular na fase aguda da AZy.CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel SuperiorConselho Nacional de Desenvolvimento CientÃfico e TecnolÃgicohttp://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=57application/pdfinfo:eu-repo/semantics/openAccessporreponame:Biblioteca Digital de Teses e Dissertações da UFCinstname:Universidade Federal do Cearáinstacron:UFC2019-01-21T11:13:10Zmail@mail.com - |
dc.title.pt.fl_str_mv |
ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos. |
dc.title.alternative.en.fl_str_mv |
Nitric oxide (NO) participation in central hyperralgesia modulation in modulation in the zymozan induced artritis (AZy) in rats. |
title |
ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos. |
spellingShingle |
ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos. VirgÃnia ClÃudia Carneiro GirÃo Artrite Dor Ãxido NÃtrico Artritis Pain Nitric Oxide FARMACOLOGIA |
title_short |
ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos. |
title_full |
ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos. |
title_fullStr |
ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos. |
title_full_unstemmed |
ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos. |
title_sort |
ParticipaÃÃo do Ãxido nÃtrico (NO) na modulaÃÃo central da hiperalgesia na artrite induzida por zymozan (AZy) em ratos. |
author |
VirgÃnia ClÃudia Carneiro GirÃo |
author_facet |
VirgÃnia ClÃudia Carneiro GirÃo |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Francisco Airton Castro da Rocha |
dc.contributor.advisor1ID.fl_str_mv |
23373474353 |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/4916026652021507 |
dc.contributor.referee1.fl_str_mv |
Geanne Matos de Andrade |
dc.contributor.referee1ID.fl_str_mv |
21911258320 |
dc.contributor.referee1Lattes.fl_str_mv |
http://lattes.cnpq.br/9935129797137635 |
dc.contributor.referee2.fl_str_mv |
Carlos MaurÃcio de Castro Costa |
dc.contributor.referee2ID.fl_str_mv |
01356810306 |
dc.contributor.referee2Lattes.fl_str_mv |
http://lattes.cnpq.br/9291210203141568 |
dc.contributor.referee3.fl_str_mv |
Diana CÃlia Sousa Nunes-Pinheiro |
dc.contributor.referee3ID.fl_str_mv |
15563278387 |
dc.contributor.referee3Lattes.fl_str_mv |
http://lattes.cnpq.br/3376562859305916 |
dc.contributor.referee4.fl_str_mv |
Maria Josà Pereira Vilar |
dc.contributor.referee4ID.fl_str_mv |
15479110420 |
dc.contributor.referee4Lattes.fl_str_mv |
http://lattes.cnpq.br/4265369922470937 |
dc.contributor.authorID.fl_str_mv |
46447512353 |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/5491102217675347 |
dc.contributor.author.fl_str_mv |
VirgÃnia ClÃudia Carneiro GirÃo |
contributor_str_mv |
Francisco Airton Castro da Rocha Geanne Matos de Andrade Carlos MaurÃcio de Castro Costa Diana CÃlia Sousa Nunes-Pinheiro Maria Josà Pereira Vilar |
dc.subject.por.fl_str_mv |
Artrite Dor Ãxido NÃtrico |
topic |
Artrite Dor Ãxido NÃtrico Artritis Pain Nitric Oxide FARMACOLOGIA |
dc.subject.eng.fl_str_mv |
Artritis Pain Nitric Oxide |
dc.subject.cnpq.fl_str_mv |
FARMACOLOGIA |
dc.description.sponsorship.fl_txt_mv |
CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior Conselho Nacional de Desenvolvimento CientÃfico e TecnolÃgico |
dc.description.abstract.por.fl_txt_mv |
We investigate in this work the role of the central nervous system in the modulation of the inflammatory peripheral pain in the zymosan induced arthritis (AZy) in rats. Cerebrospinal fluid (CSF) and sinovial fluid were collected from animals at different AZy times (1, 3, 6, 12 and 14 hours) in order to determine the nitrite level. Different groups of male, Wistar rats (n=6), 250 to 300g weight, were then submitted to surgery in order to place a cannula in the subarachnoid space, to allow for intrathecal (i.t) insertion of substances. The animals were also submitted to AZy followed by the paw suspension test (PST) that measures articular incapacitation (AI), aiming to analyze hyperalgesia in this experimental model. The pharmacological modulation was achieved by the prophylactic or therapeutic i.t administration of a NO donor (SIN-1), NOS inhibitors (L-NAME, 1400W), a soluble Guanylate cyclase inhibitor (ODQ), a GMPc analogue (8-Bromo-GMPc) and an NMDA receptor antagonist (MK-801). The ODQ was also administered intraarticulary to one group of animals. The results are expressed as mean  s.e.m, followed by ANOVA and the Tukey test, comparing to the groups that received the vehicle. The levels of nitrite in the CSF were smaller at 1 and 3 hours after zymosan injection, as compared with basal levels (P<0.05). The surgical procedure did not alter hyperalgesia. SIN-1 i.t (10 mcg) reduced the AI, while 40mcg increased the AI (P<0.05). L-NAME or 1400W, prophylactic or therapeutic, reduced the AI (P<0.05). ODQ i.t, prophylactic, but not therapeutic, reduced the AI, and also reverted the AI promoted by the 40mcg of SIN-1. Besides, ODQ, intraarticulary, reverted the AI promoted by the 40mcg of SIN-1, administered i.t. MK-801 i.t inhibited the AI, both caused by AZy and by the 40mcg of SIN-1. The results suggest a central endogenous anti-nociceptive role of NO in the acute articular hyperalgesia of the AZy. The NO, depending on the dose and local where it acts, may present an anti-nociceptive or pro-nociceptive effect in the AZy, both due to the activation of GMPc and the excitation of NMDA receptors. We have shown, for the first time, the existence of a peripheral-central activation way modulating the articular hyperalgesia in the AZy acute phase. Nesse trabalho, investigamos a participaÃÃo do sistema nervoso central (SNC) na modulaÃÃo da dor inflamatÃria perifÃrica na artrite induzida por zymosan (AZy) em ratos. Coletou-se o lÃquor (LCR) e lavado articular dos animais em diferentes tempos de artrite (1, 3, 6, 12 e 24 horas) para a determinaÃÃo dos nÃveis de nitrito. Em seguida, diferentes grupos de ratos (n=6) machos, Wistar, pesando entre 250 300g, foram submetidos ao procedimento cirÃrgico para colocaÃÃo de uma cÃnula no espaÃo subaracnÃideo, para permitir a administraÃÃo intratecal (i.t) de substÃncias. Os animais foram tambÃm submetidos à artrite induzida por zymosan (AZy) seguida da realizaÃÃo do teste de suspensÃo da pata (TSP) para permitir a avaliaÃÃo da incapacitaÃÃo articular (IA), refletindo a hiperalgesia no modelo. A modulaÃÃo farmacolÃgica foi realizada atravÃs da administraÃÃo i.t, de forma profilÃtica ou terapÃutica, de um doador de NO (SIN-1), de inibidores de NOS (L-NAME, 1400W), de um inibidor da guanilato ciclase solÃvel (ODQ), de um anÃlogo do GMPc (8-Bromo-GMPc) e de um antagonista dos receptores NMDA (MK-801). Em um grupo, o ODQ foi tambÃm administrado por via i.a. Os resultados foram expressos em mÃdia  e.p.m., seguida de ANOVA e Teste de Tukey, comparando-se aos grupos que receberam o veÃculo. Os nÃveis de nitrito no LCR foram menores à 1 e 3 h apÃs a injeÃÃo do zymosan, em relaÃÃo aos valores basais (P<0,05). O procedimento cirÃrgico nÃo alterou a hiperalgesia. SIN-1 i.t (10mcg) reduziu a IA, mas 40 mcg de SIN-1 aumentaram a IA (P<0,05). L-NAME ou 1400W, de forma profilÃtica ou terapÃutica, reduziram a IA (P<0,05). ODQ i.t, profilÃtico, mas nÃo terapÃutico, reduziu a IA da AZy e tambÃm reverteu a IA promovida por 40mcg de SIN-1. Ainda, ODQ, intra-articular, reverteu a IA promovida por 40mcg de SIN-1, i.t., MK-801 i.t inibiu a IA tanto da AZy quanto de 40mcg de SIN-1. Os resultados sugerem um papel antinociceptivo endÃgeno central do NO na hiperalgesia articular aguda da AZy. O NO, a depender da dose e do local de aÃÃo, pode ter efeito prà ou anti-nociceptivo, por ativaÃÃo de GMPc e excitaÃÃo de receptores NMDA. De forma inÃdita, demonstramos a existÃncia de uma via de ativaÃÃo perifÃrico-central modulando a hiperalgesia articular na fase aguda da AZy. |
description |
We investigate in this work the role of the central nervous system in the modulation of the inflammatory peripheral pain in the zymosan induced arthritis (AZy) in rats. Cerebrospinal fluid (CSF) and sinovial fluid were collected from animals at different AZy times (1, 3, 6, 12 and 14 hours) in order to determine the nitrite level. Different groups of male, Wistar rats (n=6), 250 to 300g weight, were then submitted to surgery in order to place a cannula in the subarachnoid space, to allow for intrathecal (i.t) insertion of substances. The animals were also submitted to AZy followed by the paw suspension test (PST) that measures articular incapacitation (AI), aiming to analyze hyperalgesia in this experimental model. The pharmacological modulation was achieved by the prophylactic or therapeutic i.t administration of a NO donor (SIN-1), NOS inhibitors (L-NAME, 1400W), a soluble Guanylate cyclase inhibitor (ODQ), a GMPc analogue (8-Bromo-GMPc) and an NMDA receptor antagonist (MK-801). The ODQ was also administered intraarticulary to one group of animals. The results are expressed as mean  s.e.m, followed by ANOVA and the Tukey test, comparing to the groups that received the vehicle. The levels of nitrite in the CSF were smaller at 1 and 3 hours after zymosan injection, as compared with basal levels (P<0.05). The surgical procedure did not alter hyperalgesia. SIN-1 i.t (10 mcg) reduced the AI, while 40mcg increased the AI (P<0.05). L-NAME or 1400W, prophylactic or therapeutic, reduced the AI (P<0.05). ODQ i.t, prophylactic, but not therapeutic, reduced the AI, and also reverted the AI promoted by the 40mcg of SIN-1. Besides, ODQ, intraarticulary, reverted the AI promoted by the 40mcg of SIN-1, administered i.t. MK-801 i.t inhibited the AI, both caused by AZy and by the 40mcg of SIN-1. The results suggest a central endogenous anti-nociceptive role of NO in the acute articular hyperalgesia of the AZy. The NO, depending on the dose and local where it acts, may present an anti-nociceptive or pro-nociceptive effect in the AZy, both due to the activation of GMPc and the excitation of NMDA receptors. We have shown, for the first time, the existence of a peripheral-central activation way modulating the articular hyperalgesia in the AZy acute phase. |
publishDate |
2006 |
dc.date.issued.fl_str_mv |
2006-03-15 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/doctoralThesis |
status_str |
publishedVersion |
format |
doctoralThesis |
dc.identifier.uri.fl_str_mv |
http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=57 |
url |
http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=57 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal do Cearà |
dc.publisher.program.fl_str_mv |
Programa de PÃs-GraduaÃÃo em Farmacologia |
dc.publisher.initials.fl_str_mv |
UFC |
dc.publisher.country.fl_str_mv |
BR |
publisher.none.fl_str_mv |
Universidade Federal do Cearà |
dc.source.none.fl_str_mv |
reponame:Biblioteca Digital de Teses e Dissertações da UFC instname:Universidade Federal do Ceará instacron:UFC |
reponame_str |
Biblioteca Digital de Teses e Dissertações da UFC |
collection |
Biblioteca Digital de Teses e Dissertações da UFC |
instname_str |
Universidade Federal do Ceará |
instacron_str |
UFC |
institution |
UFC |
repository.name.fl_str_mv |
-
|
repository.mail.fl_str_mv |
mail@mail.com |
_version_ |
1643295113209708544 |